The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.

@article{Serebruany2009TheIE,
  title={The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.},
  author={Victor L. Serebruany and Motoji Kogushi and Daniela Dastros-Pitei and Marcus Flather and Deepak L Bhatt},
  journal={Thrombosis and haemostasis},
  year={2009},
  volume={102 1},
  pages={111-9}
}
E5555 is a potent protease-activated receptor (PAR-1) antagonist targeting the G-coupled receptor and modulating thrombin-platelet-endothelial interactions. The drug is currently being tested in phase II trials in patients with coronary artery disease (CAD) and has potential antithrombotic and anti-inflammatory benefits. We investigated the in-vitro effects of E5555 on platelet function beyond PAR-1 blockade in healthy volunteers and CAD patients treated with aspirin (ASA) with or without… CONTINUE READING